Investor Presentaiton
ONENESS
Fespixon, a Novel Macrophage-regulating Drug Showed
Superiority to Standard Care in a Phase 3 MRCT
JAMA
The Phase 3 data have been published on the leading journal
Network Open.
Original Investigation | Diabetes and Endocrinology
Effect of a Novel Macrophage-Regulating Drug on Wound Healing
in Patients With Diabetic Foot Ulcers
A Randomized Clinical Trial
Yu-Yao Huang, MD, PhD; Ching-Wen Lin, PhD; Nai-Chen Cheng, MD, PhD; Shawn M. Cazzell, DPM; Hsin-Han Chen, MD; Kuo-Feng Huang, MD; Kwang-Yi Tung, MD;
Hsuan-Li Huang, MD; Pao-Yuan Lin, MD; Cherng-Kang Perng, MD, PhD; Bimin Shi, MD; Chang Liu, MD; Yujin Ma, MD; Yemin Cao, MD; Yanbing Li, MD; Yaoming Xue, MD;
Li Yan, MD; Qiu Li, MD; Guang Ning, MD, PhD; Shun-Cheng Chang, MD
Ref: JAMA Netw Open. 2021;4(9):e2122607 | MRCT: Multi-center randomized clinical trial
||11View entire presentation